Close Menu

NEW YORK – Ansa Biotechnologies said on Monday that it has raised $7.9 million in an oversubscribed seed funding round.

Horizon Ventures led the round, with participation from Mubadala Capital, Humboldt Fund, and additional investors.

Together with a pre-seed round in late December 2018 led by Fifty Years, Ansa has raised $9.2 million in total.

The latest funding will allow the company to accelerate development of its DNA synthesis technology, hire staff, build an R&D facility, and establish industrial partnerships.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.